Welcome to OncoQuest Inc.
OncoQuest is a private Canadian biotechnology company developing next generation of combinatorial immunotherapy products for the treatment of cancer. On April 22, 2020, OncoQuest announced a definitive agreement to sell its drug portfolio to OncoQuest Pharmaceuticals Inc. (formerly known as Dual Industrial Co., Ltd. or OQP) in exchange for OQP bonds with a notional value of US$300 million and a commitment to fund the Oregovamab Phase 3 Clinical Trial. The largest shareholder of OncoQuest Inc. is Quest PharmaTech Inc., a Canadian biotechnology company publicly traded on the TSX Venture Exchange (TSX.-V:QPT).
OncoQuest antibody technology includes a portfolio of immuno-modulatory antibodies for the treatment of cancer. These antibodies target a number of tumorigenic proteins, including CA-125, MUC 1, PSA and Her2/neu.
Phase III Clinical Study (FLORA-5) In Progress
Name of Protocol:
A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel – Carboplatin – Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) In Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma (FLORA-5/GOG-3035)
Phase 3 double-blind, placebo-controlled, multi-center study to compare the safety and efficacy of four administrations of oregovomab 2 mg IV versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with newly diagnosed ovarian cancer who have undergone optimal debulking surgery and are either pending initiation of chemotherapy (Cohort 1 – Primary Surgery) or resumption of another three cycles of chemotherapy, having already completed three cycles of neoadjuvant chemotherapy (Cohort 2 – NACT + Interval Surgery).
Published Phase II Results
Reference: Brewer et al, Gynecol Oncol;156(3):523-529, March 2020